- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02103920
A Retrospective Immunohistochemistry Study of the Expression of Glycine/ Serine Pathway Molecules in Solid Tumors
April 1, 2014 updated by: National University Hospital, Singapore
The purpose of this study is to determine the expression of molecules involved in the glycine/serine pathway using immunohistochemistry in solid tumors.
Archived paraffin-embedded pathological specimens from the Department of Pathology, NUH will be obtained.
Tissue microarray (TMA) is a high-throughput method of analysing large numbers of formalin-fixed, paraffin-embedded tumor at a minimal cost and effort.
To analyse the expression of molecules of putative relevance to the glycine/serine pathway, (such as PSPH, PSAT1, SHMT1, and GLDC), TMA technology will be utilised as previously reported (Kristiansen, Zhang, Soong).
Tissue arrays will be constructed from solid tumors including cancers of the colon/ rectum, lung, breast, cervix, ovary, endometrium, fallopian tube, prostate, kidney, testis, stomach, liver, brain and lymphoma.
One hundred cases of each tumor type (subject to availability) will be stained using immunohistochemistry. Patient Identifiers will not be collected.
Societal benefit in terms of knowledge gained to improve understanding of cancer.
No direct risk to subjects as this is a retrospective study of archived pathological tumour samples.
Study Overview
Status
Unknown
Conditions
Study Type
Observational
Enrollment (Anticipated)
1400
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Singapore, Singapore
- Recruiting
- Nationa University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Archived paraffin-embedded pathological specimens from the Department of Pathology, NUH.
Description
Inclusion Criteria:
- Patients with solid tumor cancer
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change the expression of molecules of putative relevance to the glycine/serine pathway
Time Frame: 5 years
|
Archived paraffin-embedded pathological specimens from the Department of Pathology, NUH will be obtained.
Tissue microarray (TMA) is a high-throughput method of analysing large numbers of formalin-fixed, paraffin-embedded tumor at a minimal cost and effort.
To analyse the expression of molecules of putative relevance to the glycine/serine pathway, (such as PSPH, PSAT1, SHMT1, and GLDC), TMA technology will be utilised as previously reported (Kristiansen, Zhang, Soong).
Tissue arrays will be constructed from solid tumors including cancers of the colon/ rectum, lung, breast, cervix, ovary, endometrium, fallopian tube, prostate, kidney, testis, stomach, liver, brain and lymphoma.
One hundred cases of each tumor type (subject to availability) will be stained using immunohistochemistry.
|
5 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2011
Primary Completion (Anticipated)
June 1, 2014
Study Registration Dates
First Submitted
April 2, 2012
First Submitted That Met QC Criteria
April 1, 2014
First Posted (Estimate)
April 4, 2014
Study Record Updates
Last Update Posted (Estimate)
April 4, 2014
Last Update Submitted That Met QC Criteria
April 1, 2014
Last Verified
April 1, 2014
More Information
Terms related to this study
Other Study ID Numbers
- MC01/06/11
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Tumor Cancer
-
Albert Einstein College of MedicineTerminatedCancer | Solid Tumor | Metastatic Solid Tumor | Metastatic dMMR Solid CancerUnited States
-
Shenzhen Ionova Life Sciences Co., Ltd.Merck Sharp & Dohme LLCRecruitingCancer | Solid Tumor, Adult | Solid Carcinoma | Solid Tumor, Unspecified, Adult | Cancer Metastatic | Tumor, SolidUnited States
-
Spago Nanomedical ABRecruitingSolid Tumor | Metastatic Cancer | Refractory Cancer | Locally Advanced Solid Tumor | Unresectable Solid Tumor | Recurrent Solid TumorAustralia
-
Invitae CorporationRecruitingCancer | Solid Tumor | Solid Tumor, AdultUnited States
-
Novartis PharmaceuticalsTerminatedCancer | Solid Tumor | Advanced Solid TumorJapan
-
Sairopa B.V.RecruitingMetastatic Solid Tumor | Solid Tumor, Adult | Refractory CancerUnited States, Moldova, Republic of
-
Daiichi Sankyo Co., Ltd.RecruitingSolid Tumor | Metastatic Solid Tumor | Advanced CancerJapan, United States, Canada
-
Panolos BioscienceRecruitingMetastatic Colorectal Cancer | Hepatocellular Carcinoma | Gastric Cancer | Solid Tumor | Advanced Solid Tumor | Solid Tumor, AdultKorea, Republic of
-
Imugene LimitedRecruitingSolid Tumor | Metastatic Cancer | Advanced Solid Tumor | Solid Tumor, Adult | Solid CarcinomaUnited States, Australia
-
Aadi Bioscience, Inc.RecruitingMalignant Solid Neoplasm | Neoplasms | Cancer | Neoplasm Metastasis | Solid Tumor | Metastatic Cancer | Metastasis | Advanced Solid Tumor | Metastatic Solid Tumor | Advanced Cancer | Tumor | Malignant Neoplasm | Malignant Tumor | Tumors | Cancer Metastatic | Tumor, Solid | Malignant Solid Tumor | TSC | TSC1 | TSC2 | Metastatic NeoplasmKorea, Republic of, United States, Puerto Rico